Our Services 3 - Operating model and organisational design

Our Services

What We Do

Asset and Portfolio Strategy

Customer Engagement Excellence

Operating Model

Asset and Portfolio Strategy

Customer Engagement Excellence

Operating Model

Selected Whitepapers

Optimising Patient Pathways

Health systems worldwide are under growing strain from ageing populations, rising chronic disease rates, and increasing patient expectations. In the UK, these pressures are most visible in the NHS, where workforce shortages, operational bottlenecks, and rising demand make transformation difficult. In our white paper, “Optimising Healthcare Pathways: Bridging Innovation and Delivery to Transform Patient Care,” we explore how healthcare leaders can address these challenges – by aligning clinical, operational, and industry expertise, leveraging data-driven insights, embedding innovation into daily practice, and unlocking the full potential of the life sciences sector. The result of this is a triple win for patients, healthcare systems and industry.

Early Strategic Planning for Biotechs

Biotechs have overtaken pharma as the key contributor of molecules to the global R&D pipeline. However, they are facing an increasingly unforgiving commercial landscape characterised by rising R&D costs, lowering success rates and longer clinical trials causing 60% of biotechs to fail within 5 years of their inception. In our latest white paper, “Early Strategic Planning for Biotechs: How to Overcome Future Commercialisation Challenges Through Effective Planning”, we explore how Biotech leaders can tackle these challenges – by working backwards from the patient need, embracing patient-centric strategy, leveraging new technologies, and attracting the right leaders.

Insights and Patient Journeys: Building the Foundation of Effective Planning

Insights are crucial for product success. In today’s competitive market, it’s essential to accurately identify and address unmet stakeholder needs. However, many companies struggle with siloed insights, duplication of effort, and poor internal alignment. Our white paper, “Insights and Patient Journeys: Building the Foundation of Effective Planning”, outlines a patient journey-based approach to organise and assess insights, informing strategy and brand planning. This helps to ensure that the patient remains central to the decision-making process, whilst also placing insights within the broader context of the treatment journey.

Empowering MSLs to deliver better scientific engagements

HCPs’ increasing reliance on the scientific expertise of MSLs is positioning the role as an essential strategic resource for Pharma companies. This trend has resulted in a boom in the number of MSLs across the industry – since 2010 MSL headcount has increased by 300%. However, many Medical Affairs teams remain underfunded and struggle to provide MSLs the support and resources they need to effectively carry out their impactful work. Oliver Spray has written a white paper titled “Empowering MSLs to deliver better scientific engagements”, which examines three challenges MSLs face in delivering impactful HCP engagements as well as providing proposals to Pharma on how to overcome them.

An Analysis of Investigator Sponsored Study Cycle Times: Communication is the key for success

Pharmaceutical companies conduct evidence generation activities within Medical Affairs through Investigator Sponsored (ISS), Company Sponsored (CSS), and Collaborative Research Studies (CRS). The timely completion of these studies is vital to generate relevant evidence for the wider scientific community; and helps to ensure that studies complete on budget.

Trial decentralisation: The benefits and challenges

Over the course of the pandemic the use of Decentralised Clinical Trials (DCT) increased significantly, with around 87% of sponsors and contract research organisations conducting or planning to conduct trials with decentralised aspects – compared to 28% prior to the pandemic. The primary driver for this shift was to avoid delays in clinical trials that included vulnerable patients that were unwilling or unable to come onto site. As the adoption of trial decentralisation rises, a number of challenges have presented themselves…